key: cord-0279832-kkqc1jx0
authors: Cheng, C.-J.; Lu, C.-Y.; Chang, Y.-H.; Sun, Y.; Chu, H.-J.; Lee, C.-Y.; Liu, C.-H.; Lin, C.-H.; Lu, C.-J.; Li, C.-Y.
title: Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till June 30, 2021
date: 2021-08-28
journal: nan
DOI: 10.1101/2021.08.23.21262500
sha: f5ae3e5f71fa72e2a3ee9937e3c90a6082501b4a
doc_id: 279832
cord_uid: kkqc1jx0

Objective: Large clinical trials have proved the efficacy of Covid-19 vaccine, and the number of literature about the effectiveness is rapidly growing in the first half of year after mass vaccination was administrated globally. This rapid review aims to provide evidence syntheses as a means to complement the current evidence on the vaccine effectiveness (VE) against various outcomes in real-world settings. Methods: This review is conducted based on the updated guideline of PRISMA 2020. Databases (PubMed, EMBASE, and MedRxiv) were searched up to 30 June 2021, (PROSPERO ID: 266866). The studies that assessed the VE of the 6 WHO-authorized vaccines (BNT162b2, ChAdOx1, Ad26.COV2.S, mRNA-1273, BBIBP-CorV, and CoronaVac) were eligible to be included. Quality assessment was performed based on ROBINS-I by 2 independent reviewers. Findings: A total of 39 studies were included, covering over 15 million of participants from 11 nations. Among the general population after 2 doses of vaccination, the VE against symptomatic SARS-CoV-2 infection was estimated at 89%-97%, 92% (95% CI, 78%-97%) and 94% (95% CI, 86%-97%) for BNT162b2, ChAdOx1 and mRNA-1273, respectively. As for the protective effects against B.1.617.2 related symptomatic infection, the VE was 88% (95% CI, 85.3%-90.1%) by BNT162b2 and 67.0% (95% CI, 61.3%-71.8%) by ChAdOx1 after fully vaccination. Conclusion: This review revealed a consistently high effectiveness of vaccines among the general population in real-world settings. Further studies are needed to provide the information on different races/ethnicity, the effects against SARS-CoV-2 variants, and the duration of protection with longer study time.

Large randomized control trials have demonstrated efficacy against SARS-CoV-2 infection to be 70%, 94%, 95%, and 78% after two doses of ChAdOx1 (Oxford/AstraZeneca), mRNA-1273 (Moderna), BNT162b2 (BioNTech/Pfizer), and BBIBP-CorV (Sinopharm) vaccines, respectively. [1] [2] [3] [4] Single-dose of Ad26.COV2.S (Johnson & Johnson) vaccine yielded an efficacy of 81.7% against severe-critical Covid-19 disease. 5 Based on the good results from clinical trials, Covid-19 vaccination programs have been extensively rolled out in many countries around the world. But over the first half-year since vaccine administration globally, most countries have fully vaccination rates less than 50%. 6 Billions of people in the world are eagerly waiting for the Covid-19 vaccines on one hand, and questioning about how well the vaccines work in the real world on the other hand. As relevant study reports being released successively, a wide range of vaccine effectiveness (VE) has been noticed. The estimated effectiveness after full vaccination could range from 9 2021. Distributions of the VE estimates derived from the included studies were further graphically presented by Box plots, according to study population, brand of vaccine, variant, number of dose, and outcome.

Of 2369 searched articles (2085 from PubMed, 195 from EMBASE, and 89 preprints from MedRxiv), 2312 were excluded while screening on abstracts and titles. After a full-text review on the remaining 57 articles for eligibility, 39 studies 8, 10, 11, 14-49 that met the inclusion criteria were included in this rapid review (Fig. 1, Supplementary Table S1). Results of quality assessment of all the included studies were shown in Supplementary Table S2 . Before July 1, 2021, 24 of 39 studies are published in peer-reviewed journals 8, 11, 14-16, 18, 21, 23, 24, 27-30, 32, 33, 35, 36, 39-41, 46, 47, 49, 50 while the rest 15 studies are posted online as preprint articles. 10, 17, 19, 20, 22, 25, 26, 31, 34, 37, 38, 42, 43, 45, 48 The characteristics of studies were shown in Supplementary Table S1, including country, study design, types of vaccines, outcomes, and SARS-CoV-2 variants involved in studies. The outcomes include all laboratory-confirmed SARS-CoV-2 infection, asymptomatic and symptomatic infection, hospitalization, critical disease, and death. As for evaluating the protective effects of the vaccine on SARS-CoV-2 variants, 5 studies mentioned the approximate prevalence of variants in the region of . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 study population, 17, 18, 27, 33, 48 and 11 studies calculated the number or percentage of cases with variants among all or sampled participants with a positive test of 25, 30, 32, [35] [36] [37] 41, 42, 45, 47 Only 3 studies evaluated the VE against specific VOC, in which one study from Qatar reported the VE against B. 

The characteristics of studies and their VE estimates against overall SARS-CoV-2 infection among general and specific populations are shown in Table 1 Among partially vaccinated general population, the VE varied among studies (42%-78% by BNT162b2, 22, 27, 30, 39, 41, 51, 52 67%-93% by mRNA-1273 25, 30, 39 and 61%-95% by ChAdOx1 30, 31, 41 ). After full vaccination, the VE was all higher than 75% (77%-98% by BNT162b2, 10, 22, 27, 30, 32, 39, 41 (Table 1) . 42 The VE among fully vaccinated healthcare workers was . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 28, 2021.

80% or higher (80%-97% by BNT162b2 10, 18, 21, 29, 33, 38, 46, 47 (Table 3) .

The VE estimates against SARS-CoV-2 related various outcomes were shown in is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 28, 2021. ;  infection with predominant P.1 variant (37%, 95% CI, 54.9%−74.2%) even after being fully vaccinated (Fig. 4 , Table 2 ). 34 The protective effects become more obvious for more severe outcomes. The VE against critical disease was higher than 90% by BNT162b2. 27, 32, 39 A study even demonstrated a VE of 100% for subjects who were fully vaccinated with mRNA-1273 (Fig. 5) . 39 Regarding the risk reduction in hospitalization among the general population, the effectiveness was similar among one dose of ChAdOx1 (VE: 88%-100%), 30, 49 two doses of BNT162b2 (VE: 87%-99%), 10, 27, 32, 49 and two doses of mRNA-1273 (VE: 86%-100%) (Fig. 6) . 30, 39 Risk reduction of death for more than 95% was also found by one dose of ChAdOx1 and 2 doses of mRNA vaccines (Fig. 7) . The VE estimates against Covid-19 hospital admissions after vaccination either with BNT162b2 or ChAdOx1 in older age groups were slightly lower than that of younger age groups. 49 The result of VE across age groups was shown in Supplementary Table S3 . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 28, 2021. ; 13 54.0%-75.0%]) in terms of preventing symptomatic infection. 53

This rapid review included 39 studies from 11 countries. Some of these studies may have overlapping populations with data obtained from the same datasets (e.g. national registry) or from the same institution or same region. 14-16, 18-20, 27, 31, 33, 35-38, 40, 41, 44 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. ;

The suboptimal VE observed in the elderly or residents of long-term care facility are probably due to the immunosenescence which leads to defects in innate and adaptive immune responses. Vaccine responses tended to be weaker and decline earlier 54 with a lower titer of antibodies. 55-57 Since they are vulnerable to developing SARS-CoV-2 infections and its complications, improved vaccine strategies or further vaccine boosting are required in these vulnerable populations.

It should be noted that VE between vaccines cannot be directly compared across these papers due to the following reasons. The first one is the heterogeneity in the interval between vaccination and start of event measurement. The VE of the first dose BNT162b2 against infection was 61% ≥ 14 days after the vaccination in the study by Pawlowski et al. 39 and was 72% ≥ 21 days after vaccination in the study by Hall et al. 33 For immunity is gradually building, 3 the protective effects would increase over a given period of time. 17, 27 At present, there is no data to suggest the timing of the VE plateauing for each vaccine. Second, a large variation is noted regarding the dosing intervals. To vaccinate as many people as possible, the UK government decided that the dosing interval for vaccines (whether BNT162b2 or ChAdOx1) could be extended up to 12 weeks. 20, 36 In Canada, the administration of the second dose of BNT162b2 and mRNA-1273 was delayed by up to 16 weeks for most individuals due to the disruption of vaccine supply. 25 There is limited data about the change of the effectiveness for extended dosing intervals. Variations in dosing intervals would be . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. ;  very common in most countries of the world due to the insufficient and unstable vaccine supply. Evidences regarding the effectiveness with appropriate and tolerable dosing intervals are needed. 58, 59 Third, some studies 11, 28, 37, 40, 43, 48 estimated the VE by pooled analyses of two vaccines, in which we cannot obtain the VE of each type of vaccines. Fourth, population bias with unmatched control arm or unequal use of vaccine types across study cohorts could make the data of direct comparison of vaccine types unreliable. 19, 31, 36, 39, 49 Different vaccines may target different populations in the roll-out period. For example, old age and healthcare workers are in the priority group of vaccination program in most of the countries, but the timescale of supply was different between vaccine types. 17, 31 Although the demographic factors were controlled in most studies, residual confounding may not be entirely excluded.

There are several barriers and limitations in this study. First, literature about the VE against Covid-19 are rapidly evolving and growing exponentially. In this review, 15 of 39 included studies are preprint articles up to June 30, 2021. While we were processing the review and extracting the data in July, five studies have been accepted with their data changed in online version 19, 31, 34, 37, 45, [51] [52] [53] 60 so that we need to constantly update the data accordingly before submission. Second, these included studies were disproportionately from countries in Europe, North America, and Israel, and were mostly focused on BNT162b2, because these countries have higher priority and access to a large amount of Covid-19 vaccines than most countries in other . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. ;  regions in the first half of 2021. 6 In addition, shorter dosing intervals and larger vaccine supply in these nations also make the data of VE associated with BNT162b2 much more comprehensive than other vaccines. Longer dosing intervals made the full vaccination reports of ChAdOx1 much fewer in number than those on mRNA vaccines among the included articles over the past months. Furthermore, the VE assessment reports on CoronaVac and Ad26.COV2.S are also too few to draw conclusions. Third, the heterogeneity across studies in dosing interval, timing of outcome measurement, or different target population between vaccine types due to supply chain issues make meta-analyses difficult at present. Fourth, the VE estimates of all the studies were based on relatively short study time (range, <2 months to 6 months) with a median follow-up period ranging from 28 to 106 days. 14, 15, 21, 32, 33, 38, 39, 46 Further studies are needed to clarify the duration of protective effects of vaccines.

The last but not the least important point is the scarce VE reports about the emerging variants such as delta variant which has been currently dominating in the whole world.

Based on the studies of the first half-year of vaccine administration, this rapid review provided timely and comprehensive evidence on the effectiveness of the ChAdOx1, BNT162b2, and mRNA-1273 vaccines against various Covid-19 infection-related . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. ; https://doi.org/10.1101/2021.08.23.21262500 doi: medRxiv preprint outcomes ranging from asymptomatic to critical illness and death. This review highlights the VE across different segments of populations. These real-world results tended to support the implementation of mass vaccination campaigns as public health strategies, and may also help ease skepticism about VE, which is still a common problem in many parts of the world.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. ; . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 28, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

ChAdOx1 Overall infection N/A 64%

BNT162b2 Overall infection N/A N/A 7 86% (78%-91%) 180766/ 51092 SCC BNT162b2 Overall infection N/A N/A 7 71%